← Leaderboards
Theodore S Lawrence
University Of Michigan At Ann Arbor
$30,022,406
Attributed
$40,103,592
Total exposure
31
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$73,217,833 · 34
By mechanism
P01$29,329,939 · 11
R01$17,273,413 · 8
P30$13,956,719 · 5
P50$8,191,879 · 5
U01$2,973,372 · 1
M01$892,511 · 3
Top collaborators
- Randall K Ten Haken15 shared
- Mukesh K. Nyati8 shared
- Jonathan Maybaum6 shared
- James Michael Balter5 shared
- Yue Cao5 shared
- James A Hayman5 shared
- Marc Lewis Kessler5 shared
- Jean Marie Moran5 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Max S. Wicha$49,028,071
- James Michael Balter$4,444,837
- Sally A. Camper$22,265,378
- William D Ensminger$1,661,564
- Eric R. Fearon$27,558,344
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorClinical ResearchDoseBaseRadiationRadiation TherapyResponseClinical TrialsPre-ClinicalDesignProgramsToxic EffectTissuesConformal RadiotherapyChemotherapyOrganMalignant NeoplasmsResistanceAreaInstructionNeoplastic CellNormal Tissue MorphologyImageFuture
Grant awards (152)
Molecularly Targeted Radiosensitization of Locally Advanced Cancers$2,027,150
P50 · FY2025 · CA · contact PI
Targeting Stromal Influences on BCKA Addiction in PDAC Tumors$574,113
R01 · FY2025 · CA
Ablating Liver Metastases with SBRT to Enhance Immune Checkpoint Blockade in Melanoma$420,670
R01 · FY2025 · CA · contact PI
Administrative Core$199,429
P50 · FY2025 · CA · contact PI
Translational and Clinical Research (TACR)$120,223
P30 · FY2025 · CA · contact PI
Ablating Liver Metastases with SBRT to Enhance Immune Checkpoint Blockade in Melanoma$82,478
R01 · FY2025 · CA · contact PI
Molecularly Targeted Radiosensitization of Locally Advanced Cancers$1,946,064
P50 · FY2024 · CA · contact PI
Ablating Liver Metastases with SBRT to Enhance Immune Checkpoint Blockade in Melanoma$542,305
R01 · FY2024 · CA · contact PI
Targeting Stromal Influences on BCKA Addiction in PDAC Tumors$534,216
R01 · FY2024 · CA
Development of a first-in-class mEGFR dimerization inhibitor$398,262
R01 · FY2024 · CA
Development of a first-in-class mEGFR dimerization inhibitor$351,000
R01 · FY2024 · CA
Administrative Core$191,452
P50 · FY2024 · CA · contact PI
Translational and Clinical Research (TACR)$115,633
P30 · FY2024 · CA · contact PI
Molecularly Targeted Radiosensitization of Locally Advanced Cancers$2,066,150
P50 · FY2023 · CA · contact PI
Targeting Stromal Influences on BCKA Addiction in PDAC Tumors$579,715
R01 · FY2023 · CA
Development of a first-in-class mEGFR dimerization inhibitor$410,837
R01 · FY2023 · CA
Development of a first-in-class mEGFR dimerization inhibitor$351,000
R01 · FY2023 · CA
Administrative Core$192,381
P50 · FY2023 · CA · contact PI
Translational and Clinical Research (TACR)$118,156
P30 · FY2023 · CA · contact PI
Targeting Stromal Influences on BCKA Addiction in PDAC Tumors$581,396
R01 · FY2022 · CA
Development of a first-in-class mEGFR dimerization inhibitor$410,837
R01 · FY2022 · CA
Development of a first-in-class mEGFR dimerization inhibitor$351,000
R01 · FY2022 · CA
Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response$582,111
U01 · FY2021 · CA · contact PI
Development of a first-in-class mEGFR dimerization inhibitor$419,222
R01 · FY2021 · CA
Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response$582,111
U01 · FY2020 · CA · contact PI
Development of a first-in-class mEGFR dimerization inhibitor$419,222
R01 · FY2020 · CA
Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response$564,647
U01 · FY2019 · CA · contact PI
Optimization of High Dose Conformal Therapy$2,748,478
P01 · FY2018 · CA
SARRP for Multimodality Image-Guided Stereotactic Irradiation$600,000
S10 · FY2018 · OD · contact PI
Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response$581,178
U01 · FY2018 · CA · contact PI
Administration and Statistics$422,937
P01 · FY2018 · CA
Response-Driven, Knowledge-based, Adaptive Plan Optimization$411,724
P01 · FY2018 · CA
Imaging-Based Assessments of Response$376,401
P01 · FY2018 · CA
Response-driven Treatment of Hepatocellular Carcinoma$342,669
P01 · FY2018 · CA · contact PI
Quantitative Image Analysis, Processing and Management$315,843
P01 · FY2018 · CA
Computer Software Support$313,634
P01 · FY2018 · CA
Response-driven Treatment of Non-Small Cell Lung Cancer$284,669
P01 · FY2018 · CA
Treatment Verification and Treatment Plan Refinement$280,601
P01 · FY2018 · CA
Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response$84,946
U01 · FY2018 · CA · contact PI
Optimization of High Dose Conformal Therapy$2,754,436
P01 · FY2017 · CA
Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response$578,379
U01 · FY2017 · CA · contact PI
Administration and Statistics$428,872
P01 · FY2017 · CA
Response-Driven, Knowledge-based, Adaptive Plan Optimization$411,727
P01 · FY2017 · CA
Imaging-Based Assessments of Response$376,405
P01 · FY2017 · CA
Response-driven Treatment of Hepatocellular Carcinoma$342,673
P01 · FY2017 · CA · contact PI
Quantitative Image Analysis, Processing and Management$315,846
P01 · FY2017 · CA
Computer Software Support$313,637
P01 · FY2017 · CA
Response-driven Treatment of Non-Small Cell Lung Cancer$284,672
P01 · FY2017 · CA
Treatment Verification and Treatment Plan Refinement$280,604
P01 · FY2017 · CA
Optimization of High Dose Conformal Therapy$2,748,478
P01 · FY2016 · CA
University of Michigan Comprehensive Cancer Center Support Grant$499,325
P30 · FY2016 · CA · contact PI
Administration and Statistics$422,937
P01 · FY2016 · CA
Response-Driven, Knowledge-based, Adaptive Plan Optimization$411,724
P01 · FY2016 · CA
Imaging-Based Assessments of Response$376,401
P01 · FY2016 · CA
Response-driven Treatment of Hepatocellular Carcinoma$342,669
P01 · FY2016 · CA · contact PI
Quantitative Image Analysis, Processing and Management$315,843
P01 · FY2016 · CA
Computer Software Support$313,634
P01 · FY2016 · CA
Response-driven Treatment of Non-Small Cell Lung Cancer$284,669
P01 · FY2016 · CA
Treatment Verification and Treatment Plan Refinement$280,601
P01 · FY2016 · CA
University of Michigan Comprehensive Cancer Center Support Grant$198,450
P30 · FY2016 · CA · contact PI
University of Michigan Comprehensive Cancer Center Support Grant$6,097,616
P30 · FY2015 · CA · contact PI
Optimization of High Dose Conformal Therapy$2,755,905
P01 · FY2015 · CA
Administration and Statistics$429,101
P01 · FY2015 · CA
Response-Driven, Knowledge-based, Adaptive Plan Optimization$411,948
P01 · FY2015 · CA
Imaging-Based Assessments of Response$376,606
P01 · FY2015 · CA
Response-driven Treatment of Hepatocellular Carcinoma$342,855
P01 · FY2015 · CA · contact PI
Quantitative Image Analysis, Processing and Management$316,014
P01 · FY2015 · CA
Computer Software Support$313,804
P01 · FY2015 · CA
Response-driven Treatment of Non-Small Cell Lung Cancer$284,823
P01 · FY2015 · CA
Treatment Verification and Treatment Plan Refinement$280,754
P01 · FY2015 · CA
University of Michigan Comprehensive Cancer Center Support Grant$198,450
P30 · FY2015 · CA · contact PI
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer$192,653
R01 · FY2015 · CA
University of Michigan Comprehensive Cancer Center Support Grant$5,914,688
P30 · FY2014 · CA · contact PI
Optimization of High Dose Conformal Therapy$2,723,793
P01 · FY2014 · CA
Administration and Statistics$422,849
P01 · FY2014 · CA
Response-Driven, Knowledge-based, Adaptive Plan Optimization$411,639
P01 · FY2014 · CA
Imaging-Based Assessments of Response$376,323
P01 · FY2014 · CA
Response-driven Treatment of Hepatocellular Carcinoma$342,598
P01 · FY2014 · CA · contact PI
Computer Software Support$313,569
P01 · FY2014 · CA
University of Michigan Comprehensive Cancer Center Support Grant$310,728
P30 · FY2014 · CA · contact PI
Quantitative Image Analysis, Processing and Management$291,662
P01 · FY2014 · CA
Response-driven Treatment of Non-Small Cell Lung Cancer$284,610
P01 · FY2014 · CA
Treatment Verification and Treatment Plan Refinement$280,543
P01 · FY2014 · CA
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer$231,701
R01 · FY2014 · CA
P3 - Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer$80,098
P50 · FY2014 · CA · contact PI
University of Michigan Comprehensive Cancer Center Support Grant$74,531
P30 · FY2014 · CA · contact PI
University of Michigan Comprehensive Cancer Center Support Grant$49,999
P30 · FY2014 · CA · contact PI
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer$412,452
R01 · FY2013 · CA
P3 - Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer$166,496
P50 · FY2013 · CA · contact PI
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer$440,121
R01 · FY2012 · CA
Integration of EGFR Inhibitors with Radiochemotherapy$207,495
P50 · FY2012 · CA · contact PI
P3 - Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer$103,577
P50 · FY2012 · CA · contact PI
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer$316,600
R01 · FY2011 · CA
Integration of EGFR Inhibitors with Radiochemotherapy$198,020
P50 · FY2011 · CA · contact PI
P3 - Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer$110,356
P50 · FY2011 · CA · contact PI
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer$413,920
R01 · FY2010 · CA
INDIVIDUALIZED DOSE ESCALATION IN VOLUME-EFFECT ORGANS$408,009
P01 · FY2010 · CA · contact PI
Gemcitabine-Radiation for Advanced Pancreatic Cancer$343,925
R01 · FY2010 · CA · contact PI
Integration of EGFR Inhibitors with Radiochemotherapy$226,373
P50 · FY2010 · CA · contact PI
P3 - Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer$110,810
P50 · FY2010 · CA · contact PI
EXPERIMENTAL IRRADIATION$60,060
P30 · FY2010 · CA · contact PI
Gemcitabine-Radiation for Advanced Pancreatic Cancer$487,829
R01 · FY2009 · CA · contact PI
INDIVIDUALIZED DOSE ESCALATION IN VOLUME-EFFECT ORGANS$403,976
P01 · FY2009 · CA · contact PI
Gemcitabine-Radiation for Advanced Pancreatic Cancer$343,925
R01 · FY2009 · CA · contact PI
Integration of EGFR Inhibitors with Radiochemotherapy$228,678
P50 · FY2009 · CA · contact PI
Gemcitabine-Radiation for Advanced Pancreatic Cancer$139,473
R01 · FY2009 · CA · contact PI
EXPERIMENTAL IRRADIATION$59,676
P30 · FY2009 · CA · contact PI
INDIVIDUALIZED DOSE ESCALATION IN VOLUME-EFFECT ORGANS$395,478
P01 · FY2008 · CA · contact PI
Gemcitabine-Radiation for Advanced Pancreatic Cancer$343,925
R01 · FY2008 · CA · contact PI
Integration of EGFR Inhibitors with Radiochemotherapy$137,350
P50 · FY2008 · CA · contact PI
EXPERIMENTAL IRRADIATION$33,104
P30 · FY2008 · CA · contact PI
Liver Radioprotection by Systemic of Regional Amifostine$455,758
R01 · FY2007 · CA · contact PI
INDIVIDUALIZED DOSE ESCALATION IN VOLUME-EFFECT ORGANS$394,638
P01 · FY2007 · CA · contact PI
Gemcitabine-Radiation for Advanced Pancreatic Cancer$343,925
R01 · FY2007 · CA · contact PI
HIGH DOSE RADIATION & HEPATIC ARTERIAL FLOXURIDINE IN INTRAHEPATIC MALIGNANCIES$59,651
M01 · FY2007 · RR · contact PI
EXPERIMENTAL IRRADIATION$33,104
P30 · FY2007 · CA · contact PI
Liver Radioprotection by Systemic of Regional Amifostine$458,902
R01 · FY2006 · CA · contact PI
HIGH DOSE RADIATION & HEPATIC ARTERIAL FLOXURIDINE IN INTRAHEPATIC MALIGNANCIES$298,917
M01 · FY2006 · RR · contact PI
Improving gene therapy-mediated radiosensitization$277,939
R01 · FY2006 · CA · contact PI
INDIVIDUALIZED DOSE ESCALATION IN VOLUME-EFFECT ORGANS$265,658
P01 · FY2006 · CA · contact PI
EXPERIMENTAL IRRADIATION$72,976
P30 · FY2006 · CA · contact PI
Liver Radioprotection by Systemic of Regional Amifostine$452,949
R01 · FY2005 · CA
Gemcitabine-Radiation for Advanced Head and Neck Cancer$335,407
R01 · FY2005 · CA
RADIATION DOSE ESCALATION FOR FOCAL LIVER CANCER$316,579
R01 · FY2005 · CA
HIGH DOSE RADIATION &HEPATIC ARTERIAL FLOXURIDINE IN INTRAHEPATIC MALIGNANCIES$307,242
M01 · FY2005 · RR
Improving gene therapy-mediated radiosensitization$286,643
R01 · FY2005 · CA
Liver Radioprotection by Systemic of Regional Amifostine$419,405
R01 · FY2004 · CA
Gemcitabine-Radiation for Advanced Head and Neck Cancer$335,407
R01 · FY2004 · CA
RADIATION DOSE ESCALATION FOR FOCAL LIVER CANCER$316,579
R01 · FY2004 · CA
Improving gene therapy-mediated radiosensitization$286,635
R01 · FY2004 · CA
High Dose Radiation &Hepatic Arterial Floxuridine in Intrahepatic Malignancies$226,701
M01 · FY2004 · RR
Liver Radioprotection by Systemic of Regional Amifostine$407,190
R01 · FY2003 · CA
Gemcitabine-Radiation for Advanced Head and Neck Cancer$335,407
R01 · FY2003 · CA
RADIATION DOSE ESCALATION FOR FOCAL LIVER CANCER$316,579
R01 · FY2003 · CA
Improving gene therapy-mediated radiosensitization$286,664
R01 · FY2003 · CA
Gemcitabine-Radiation for Advanced Head and Neck Cancer$335,123
R01 · FY2002 · CA
IMPROVING GENE THERAPY MEDIATED RADIOSENSITIZATION$230,835
R01 · FY2002 · CA
CLINICAL STUDIES OF HIGH DOSE CONFORMAL THERAPY$0
P01 · FY2002 · CA
OPTIMIZING GEMCITABINE MEDIATED RADIOSENSITIZATION$0
P50 · FY2002 · CA
CORE--EXPERIMENTAL IRRADIATION FACILITY$0
P30 · FY2002 · CA
PILOT--EXPERIMENTAL THERAPEUTICS$0
P30 · FY2002 · CA
RADIATION TRIAL FOR MALIGNANCY INVOLVING THE LIVER AND /OR BILE DUCTS$0
M01 · FY2002 · RR
RADIOSENSITIZATION BY GEMCITABINE$271,338
R01 · FY2001 · CA
IMPROVING GENE THERAPY MEDIATED RADIOSENSITIZATION$225,526
R01 · FY2001 · CA
PILOT--EXPERIMENTAL THERAPEUTICS$0
P30 · FY2001 · CA
CORE--EXPERIMENTAL IRRADIATION FACILITY$0
P30 · FY2001 · CA
CLINICAL STUDIES OF HIGH DOSE CONFORMAL THERAPY$0
P01 · FY2001 · CA
RADIOSENSITIZATION BY GEMCITABINE$266,484
R01 · FY2000 · CA
IMPROVING GENE THERAPY MEDIATED RADIOSENSITIZATION$219,342
R01 · FY2000 · CA
CLINICAL STUDIES OF HIGH DOSE CONFORMAL THERAPY$0
P01 · FY2000 · CA
CORE--EXPERIMENTAL IRRADIATION FACILITY$0
P30 · FY2000 · CA
RADIATION TRIAL FOR MALIGNANCY INVOLVING THE LIVER AND /OR BILE DUCTS$0
M01 · FY2000 · RR